DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oxsoralen Topical (Methoxsalen Topical) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

OXSORALEN TOPICAL drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

VIII. OVERDOSAGE

This does not apply to topical usage. In the unlikely event that the lotion is ingested, standard procedures for poisoning should be followed, including gastric lavage. Protection from UVA or daylight for hours or days would also be necessary. The patient should be kept in a darkened room.

IX. ADMINISTRATION

OXSORALEN Lotion is applied to a well-defined area of vitiligo by the physician and the area is then exposed to a suitable source of UVA. Initial exposure time should be conservative and not exceed that which is predicted to be one-half the minimal erythema dose. Treatment intervals should be regulated by the erythema response; generally once a week is recommended or less often depending on the results. The hands and fingers of the person applying the medication should be protected by gloves or finger cots to avoid photosensitization and possible burns.

Pigmentation may begin after a few weeks but significant repigmentation may require up to 6 to 9 months of treatment. Periodic re-treatment may be necessary to retain all of the new pigment. Idiopathic vitiligo is reversible but not equally reversible in every patient. Treatment must be individualized. Repigmentation will vary in completeness, time of onset, and duration. Repigmentation occurs more rapidly in fleshy areas such as face, abdomen, and buttocks and less rapidly over less fleshy areas such as the dorsum of the hands or feet.

IV. CONTRAINDICATIONS

  1. Patients exhibiting idiosyncratic reactions to psoralen compounds or a history of sensitivity reactions to them.
  2. Patients exhibiting melanoma or with a history of melanoma.
  3. Patients exhibiting invasive skin carcinoma generally.
  4. Patients with photosensitivity diseases such as porphyria, acute lupus erythematosus, xeroderma pigmentosum, etc.
  5. Children under 12 since clinical studies to determine the efficacy and safety of treatment in this age group have not been done.

REFERENCES

  1. Artuc, M.; Stuettgen, G.; Schalla, W.; Schaefer, H.; Gazith, J.: Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro; Brit. J. Dermat., 101, pp. 669-677 (1979).
  2. Dall'Acqua, F.; Marciani, S.; Ciavatta, L.; Rodighiero, G.: formation of interstrand cross-linkings in the photoreactions between furocoumarins and DNA.; Z Naturforsch (B), 26, pp. 561-569 (1971).
  3. Yoshikawa, K; Mori, N.; Sakakibara, S.; Mizuno, N.; Song, P.: Photo-Conjugation of 8-methoxypsoralen with Proteins; Photochem & Photobiol, 29, pp. 1127-1133 (1979).
  4. Ortonne, J.P.; MacDonald, D.M.; Micoud, A.; Thivolet, J.: PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultra-structural study; Brit. J. Dermat., 101, pp. 1-12 (1979).
  5. Pathak, M.A.; Daniels, F.; Hopkins, C.E.; Fitzpatrick, T.B.: Ultraviolet carcinogenesis in albino and pigmented mice receiving furocoumarins: psoralens and 8-methoxypsoralen, Nature, 183, pp. 728-730 (1959).
  6. Lerner, A.B.; Denton, C.R.; Fitzpatrick, T.B.: Clinical and experimental studies with 8-methoxypsoralen in vitiligo; J. Invest. Derm., 20, pp. 299-314 (April, 1953).
  7. Fitzpatrick, T.B.; Arndt, K.A.; El Mofty, A.M.: Hydroquinone and psoralens in the therapy of hypermelanosis and vitiligo; Arch Derm., 93, pp. 589-599 (May, 1966).
  8. Fulton, James F.; Leyden, James; Papa, Christopher: Treatment of vitiligo with topical methoxsalen and blacklite; Arch. Derm., 101, pp. 224-229 (1969).

2398-03 EL

    Rev. 5-98

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017